CT1812,
works by a completely novel mechanism to stop the binding of toxic proteins
that build up in the brains of Alzheimer's patients known as Abeta oligomers.
CT1812,
a novel oligomer receptor antagonist is the only drug candidate that has demonstrated
not only prevention but it also displaces binding of Abeta oligomers to
receptors on brain cells. By stopping the initiating event in the Abeta
oligomer cascade, this first-in-class drug candidate completely blocks
downstream synaptotoxicity and restores memory to normal in aged transgenic
mouse models of Alzheimer's disease.
CT1812
is an orally administered lipophilic isoindoline formulated as a fumarate salt
that is rapidly absorbed and highly brain penetrant. It displaces
receptor-bound Abeta oligomers by allosterically antagonizing the
sigma-2/PGRMC1 receptor. CT1812 thus represents the first disease-modifying
therapeutic that will test the oligomer hypothesis of Alzheimer's disease.
For
more details, order the pdf by sending an email at sharma.rajan@gmail.com.
Report has all the features that this site has provided to its users such as
structure, synthesis, and activity results.
Or else
wait for 60 days, when a part of the report will be available free.
For
FAQ’s.
